NDV-GT wth hyperacute rejection in cancer therapy

Puntos clave

• Hyperacute rejection significantly affects therapeutic outcomes in cancer treatment, limiting effectiveness.
• Key evidence indicates that NDV-GT may enhance immune response and stimulate relevant biomarkers.
• Analysis of immune response strategies highlights the dynamic interaction between NDV-GT and patient responses.
• These findings call for further investigations into the role of NDV-GT, particularly in immune-mediated reactions.